Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 7/20 | 0.63 |
| ▸ | CES2 | O00748 | 6/20 | 0.63 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | ATM | Q13315 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | XBP1 | P17861 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1538140 | 0.80 | CES1 (0.68) | CES1CES2MAPTALDH1A1LMNA | |
| SCHEMBL28813199 | 0.80 | CES1 (0.44) | CES1CES2MAPTALDH1A1HPGD | |
| SCHEMBL7023587 | 0.79 | CES1 (0.45) | CES1CES2MAPTHPGDRAB9A | |
| SCHEMBL1538201 | 0.79 | CES2 (0.69) | CES1CES2MAPTLMNAL3MBTL1 | |
| SCHEMBL28177441 | 0.78 | CES1 (0.43) | CES1CES2MAPTALDH1A1HPGD | |
| SCHEMBL7669290 | 0.77 | CES2 (1.00) | CES1CES2MAPTALDH1A1RAB9A | |
| SCHEMBL4625390 | 0.77 | CES2 (1.00) | CES1CES2MAPTALDH1A1RAB9A | |
| SCHEMBL27386846 | 0.77 | CES1 (0.64) | CES1CES2MAPTALDH1A1L3MBTL1 | |
| SCHEMBL1959867 | 0.77 | CES1 (0.50) | CES1CES2MAPTALDH1A1HPGD | |
| SCHEMBL9789407 | 0.76 | LMNA (0.47) | CES1CES2MAPTALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11285135-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2022-03-29 | — | — | US | disclosed |
| US-20200069657-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2020-03-05 | — | — | US | disclosed |
| US-20180177767-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2018-06-28 | — | — | US | disclosed |
| US-20180114921-A1 | Organic Semiconducting Material Comprising an Electrical n-Dopant and an Electron Transport Matrix and Electronic Device Comprising the Semiconducting Material | NOVALED GMBH (DE) | 2018-04-26 | — | — | US | disclosed |
| CN-1140708-A | Synthetic method for lisinopril | WUZHOU PHARMACEUTICAL FACTORY (CN) | 1997-01-22 | — | — | CN | disclosed |
| WO-1992019613-A2 | 1,2-DITHIOLE-3-THIONE DERIVATIVE-BASED THERAPEUTICAL COMPOSITIONS | LABORATOIRES DE THERAPEUTIQUE MODERNE (FR) | 1992-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180114921-A1 | Organic Semiconducting Material Comprising an Electrical n-Dopant and an Electron Transport Matrix and Electronic Device Comprising the Semiconducting Material | OCIAD2, OCIAD1, DRD1 | CES1 4512/4885CES2 1737/4885MAPT 294/4885 |
| US-20200069657-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | CES1 2593/4885CES2 4882/4885MAPT 4297/4885 |
| US-11285135-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | CES1 2115/4885CES2 4882/4885MAPT 4468/4885 |
| US-20180177767-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | CES1 2554/4885CES2 4882/4885MAPT 4273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.